A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy.

Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OAK
  • Sponsors Roche
  • Most Recent Events

    • 18 Oct 2017 Results of long term survival in patients with non small cell lung cancer, presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results (n=850) assessing Teff GE association with atezolizumab efficacy in NSCLC, were presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results reporting data of symptom burden, functioning, and health-related quality of life (HRQoL) presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top